Spyre Therapeutics To Participate In Stifel 2025 Virtual Immunology And Inflammation Forum

2025-09-08 04:16:11

(MENAFN- GlobeNewsWire - Nasdaq) WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the“Company” or“Spyre”), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced that management will participate in a fireside chat and investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum. Fireside details below:

Event: Stifel 2025 Virtual Immunology and Inflammation Forum
Date: Monday, September 15, 2025
Fireside Time: 10:00 a.m. ET

Live audio webcasts and replays of these events will be available on the Spyre investor events website at .

About Spyre Therapeutics

Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at

Follow Spyre Therapeutics on social media: @spyretx and LinkedIn

For Investors :
Eric McIntyre, VP of Finance and Investor Relations
...

MENAFN08092025004107003653ID1110033631

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.